Graphene Biosensors for Depression Prediction – MUNASET Perspective
- Major depressive disorder (MDD), a leading cause of disability worldwide, is characterized by symptoms such as loss of interest and depressed mood.
- Researchers are now exploring the potential of graphene-based biosensors to address this critical need.
- The MUNASET project, coordinated by Professor Alexey Tarasov, aims to develop graphene-based devices to monitor patients undergoing therapy for depression and other psychiatric disorders.This innovative test promises to...
Graphene-Based Biosensors Offer Hope for Personalized Depression Treatment
Major depressive disorder (MDD), a leading cause of disability worldwide, is characterized by symptoms such as loss of interest and depressed mood. Despite the availability of effective treatments,individual responses vary significantly. This necessitates the advancement of reliable, accessible predictors too inform treatment decisions.Currently, no tests can predict individual treatment responses using biofluids like blood, serum, plasma, or saliva.
Researchers are now exploring the potential of graphene-based biosensors to address this critical need. Recent research on biomarkers for MDD provides an prospect to overcome the limitations of conventional diagnostic tools. Graphene and its derivatives have proven to be excellent materials for designing sensitive electrochemical and electrical biosensing platforms.
The MUNASET project, coordinated by Professor Alexey Tarasov, aims to develop graphene-based devices to monitor patients undergoing therapy for depression and other psychiatric disorders.This innovative test promises to be fast, easy to use, and require only blood samples, enabling personalized therapies at the point of care and potentially improving treatment outcomes.
“the MUNASET project aims to develop graphene-based devices to help doctors monitor patients with depression and other psychiatric disorders undergoing therapy. The envisaged test is fast and easy to use, requires only blood samples, and can be used at the point of care to develop personalised therapies.It can greatly improve treatment outcomes for psychiatric diseases.”
Integrating graphene with potential MDD biomarkers is a promising approach to creating reliable and cost-effective biosensors. Further research and development are focused on optimizing these biosensors for monitoring responses to different treatment options in MDD.
For further facts, contact Thomas zadrozny, Exploitation Manager, MUNASET project, ProActive ltd, Brussels, belgium. Email: t.zarozny@mail.be